TY - JOUR
T1 - Serum lactate as a novel potential biomarker in multiple sclerosis
AU - Amorini, Angela M.
AU - Nociti, Viviana
AU - Petzold, Axel
AU - Gasperini, Claudio
AU - Quartuccio, Esmeralda
AU - Lazzarino, Giacomo
AU - Di Pietro, Valentina
AU - Belli, Antonio
AU - Signoretti, Stefano
AU - Vagnozzi, Roberto
AU - Lazzarino, Giuseppe
AU - Tavazzi, Barbara
PY - 2014
Y1 - 2014
N2 - Multiple sclerosis (MS) is a primary inflammatory demyelinating disease associated with a probably secondary progressive neurodegenerative component. Impaired mitochondrial functioning has been hypothesized to drive neurodegeneration and to cause increased anaerobic metabolism in MS. The aim of our multicentre study was to determine whether MS patients had values of circulating lactate different from those of controls. Patients (n=613) were recruited, assessed for disability and clinically classified (relapsing-remitting, secondary progressive, primary progressive) at the Catholic University of Rome, Italy (n=281), at the MS Centre Amsterdam, The Netherlands (n=158) and at the S. Camillo Forlanini Hospital, Rome, Italy (n=174). Serum lactate levels were quantified spectrophotometrically with the analyst being blinded to all clinical information. In patients with MS serum lactate was three times higher (3.04±1.26mmol/l) than that of healthy controls (1.09±0.25mmol/l, p2=0.419; p
AB - Multiple sclerosis (MS) is a primary inflammatory demyelinating disease associated with a probably secondary progressive neurodegenerative component. Impaired mitochondrial functioning has been hypothesized to drive neurodegeneration and to cause increased anaerobic metabolism in MS. The aim of our multicentre study was to determine whether MS patients had values of circulating lactate different from those of controls. Patients (n=613) were recruited, assessed for disability and clinically classified (relapsing-remitting, secondary progressive, primary progressive) at the Catholic University of Rome, Italy (n=281), at the MS Centre Amsterdam, The Netherlands (n=158) and at the S. Camillo Forlanini Hospital, Rome, Italy (n=174). Serum lactate levels were quantified spectrophotometrically with the analyst being blinded to all clinical information. In patients with MS serum lactate was three times higher (3.04±1.26mmol/l) than that of healthy controls (1.09±0.25mmol/l, p2=0.419; p
KW - Clinical disability
KW - Energy penalty
KW - Mitochondrial dysfunction
KW - Multiple sclerosis
KW - Serum lactate
UR - http://www.scopus.com/inward/record.url?scp=84899791377&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2014.04.005
DO - 10.1016/j.bbadis.2014.04.005
M3 - Article
C2 - 24726946
AN - SCOPUS:84899791377
SN - 0925-4439
VL - 1842
SP - 1137
EP - 1143
JO - Biochimica et Biophysica Acta. Molecular Basis of Disease
JF - Biochimica et Biophysica Acta. Molecular Basis of Disease
IS - 7
ER -